Overview

Rheumatoid Arthritis Drugs Market Introduction

Rheumatoid Arthritis Drugs Market is estimated to value over USD 30 billion by 2027 end and register a CAGR of over 4.3% during the forecast period 2020 to 2027.

FutureWise Market Research has offered an in-depth analysis on the Rheumatoid Arthritis Drugs Market. It provides a detailed synopsis of rheumatoid arthritis drugs market trends affecting the market growth. Additionally, this report offers region-wise proliferation and the graph of profitability, instrumental information pertaining to the rheumatoid arthritis drugs market share and SWOT analysis of this market. Moreover, this report provides the current market position of key market players in the competitive analysis of rheumatoid arthritis drugs market, while inflating their corporate strategies and provision of products.

The rheumatoid arthritis drugs market is predicted to achieve a substantial growth rate over the forecast timeframe as per the research study. The report further illustrates that this business is anticipated to register significant market numbers during the forecast period. Furthermore, this report offers key insights regarding the current overall industry valuation and it mentions the segmentation of the rheumatoid arthritis drugs market coupled with the profitable opportunities for the growth across this business vertical.

Key market players included in the rheumatoid arthritis drugs industry are Abbvie, Biogen Inc., Bristol-Myers Squibb, Celgene Corp., Celltrion Inc., Johnson & Johnson, Medimmune LLC, Merck & Co. Inc., Novartis International AG, Takeda Pharmaceutical Co. Ltd.

Rheumatoid Arthritis Drugs Market Segmentation:

By Drug Class

• Disease-Modifying Anti-Rheumatoid Drugs (DMARDs)
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Corticosteroids
• Analgesics

By Route of Administration

• Oral
• Parental

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the rheumatoid arthritis drugs market by drug class, by route of administration and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
• To forecast and evaluate micro-markets and the overall market 
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa
• To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers

Table of Contents

1 Introduction 

1.1 Objectives of the Study 

1.2 Market Definition 

        1.2.1 Markets Covered

        1.2.2 Years Considered for the Study

1.3 Currency 

1.4 Limitations 

1.5 Stakeholders 

2 Research Methodology 

2.1 Research Approach 

2.2 Research Data 

        2.2.1 Secondary Sources

                 2.2.1.1 Key Data From Secondary Sources

        2.2.2 Primary Sources

                 2.2.2.1 Key Data From Primary Sources

                 2.2.2.2 Breakdown of Primary Interviews

2.3 Market Size Estimation 

2.4 Market Breakdown and Data Triangulation 

2.5 Research Assumptions 

3 Executive Summary 

4 Rheumatoid Arthritis Drugs Market, By Drug Class

4.1 Introduction

4.2 Disease-Modifying Anti-Rheumatic Drugs (DMARDs)

4.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

4.4 Corticosteroids

4.5 Analgesics

5 Rheumatoid Arthritis Drugs Market, By Route of Administration

5.1 Introduction

5.2 Oral

5.3 Parental

6 Rheumatoid Arthritis Drugs Market, By Region

6.1 Introduction

6.2 North America

6.3 Europe

6.4 Asia Paicific

6.5 Latin America

6.6 Middle East & Africa

7 Company Profiles

7.1 Introduction

7.2 Abbvie

7.3 Biogen Inc.

7.4 Bristol-Myers Squibb

7.5 Celgene Corp.

7.6 Celltrion Inc.

7.7 Johnson & Johnson

7.8 Medimmune LLC

7.9 Merck & Co. Inc.

7.10 Novartis International AG

7.11 Takeda Pharmaceutical Company Ltd. 

8 Research Finding and Conclusion

9 Research Methodology

10 Research Data Source

Tables

Figures